Table 1.
Patient and treatment characteristics for 269 individuals with 3170 person-months of follow-up.
| Variable | Patients with data | Patients with missing data |
|---|---|---|
| Characteristic at baseline | ||
| Nonwhite ethnicity | 153 (58) | 5 (2) |
| Male sex | 214 (80) | 0 |
| Men who have sex with men | 157 (58) | 3 (1) |
| Age, median years (IQR) | 44 (38–49) | 0 |
| Antiretroviral treatment | ||
| PI | 147 (55) | 0 |
| NNRTI | 95 (35) | 0 |
| PI and NNRTI | 20 (7) | 0 |
| NRTI only | 8 (3) | 0 |
| Once daily | 35 (13) | 0 |
| Median no. of antiretroviral drugs in current regimen (IQR) | 3 (3–4) | 0 |
| Duration of current regimen, median months (IQR) | 6 (3–13) | 0 |
| Median no. of antiretroviral drugs experienced (IQR) | 4 (3–6) | 0 |
| Antiretroviral naive | 107 (40) | 0 |
| Mono- or dual-nucleoside exposure | 113 (42) | 0 |
| Characteristic during follow-up | ||
| Injection drug usea | 83 (32) | 7 (3) |
| Crack usea | 86 (33) | 11 (4) |
| Slept on street or in sheltera | 49 (19) | 11 (4) |
| Intoxication in past month, mean no. of days (3SD)b | 3.6 ± 7.6 | …c |
| Nadir CD4+ cell count, median cells/μL (IQR) | 168 (90–342) | … |
| CD4+ cell count, median cells/μL (IQR)b | 338 (195–532) | … |
| Pillbox organizer use, person-months (%) | 1371 (43) | …d |
| Viral load ≤400 copies/mL, person-months (%) | 1431 (45) | …e |
| Viral load, median log10 copies/mL (IQR) | 2.3 (1.0–4.1) | …e |
| Pill count adherence,f median % (IQR) | 86 (52–98) | …g |
NOTE. Data are no. (%) of patients, unless otherwise indicated. IQR, interquartile range; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor.
Reported in past 30 days at least once during follow-up.
Last value carried forward.
A total of 28 person-months (1% of total person-months of follow-up) lacked data.
A total of 12 person-months (0.4% of total person-months of follow-up) lacked data.
A total of 522 person-months (16% of total person-months of follow-up) lacked data.
Pill count adherence percentage was calculated as the difference between the current and previous pill counts divided by the prescribed number of doses for the same period.]
A total of 142 person-months (4% of total person-months of follow-up) lacked data.